Halozyme Therapeutics Inc (HALO)
45.65
-8.31
(-15.40%)
USD |
NASDAQ |
Nov 15, 16:00
45.65
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (TTM): 79.94M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 79.94M |
| June 30, 2024 | 78.81M |
| March 31, 2024 | 77.50M |
| December 31, 2023 | 76.36M |
| September 30, 2023 | 77.59M |
| June 30, 2023 | 76.98M |
| March 31, 2023 | 72.73M |
| December 31, 2022 | 66.61M |
| September 30, 2022 | 54.15M |
| June 30, 2022 | 45.93M |
| March 31, 2022 | 38.52M |
| December 31, 2021 | 35.67M |
| September 30, 2021 | 32.94M |
| June 30, 2021 | 32.20M |
| March 31, 2021 | 33.09M |
| December 31, 2020 | 34.24M |
| September 30, 2020 | 71.97M |
| June 30, 2020 | 94.68M |
| March 31, 2020 | 119.63M |
| December 31, 2019 | 140.80M |
| September 30, 2019 | 132.34M |
| June 30, 2019 | 137.43M |
| March 31, 2019 | 143.60M |
| December 31, 2018 | 150.25M |
| September 30, 2018 | 154.98M |
| Date | Value |
|---|---|
| June 30, 2018 | 153.43M |
| March 31, 2018 | 151.68M |
| December 31, 2017 | 150.64M |
| September 30, 2017 | 150.62M |
| June 30, 2017 | 150.49M |
| March 31, 2017 | 147.68M |
| December 31, 2016 | 150.84M |
| September 30, 2016 | 137.24M |
| June 30, 2016 | 130.99M |
| March 31, 2016 | 116.65M |
| December 31, 2015 | 93.24M |
| September 30, 2015 | 85.22M |
| June 30, 2015 | 77.51M |
| March 31, 2015 | 74.96M |
| December 31, 2014 | 79.70M |
| September 30, 2014 | 80.89M |
| June 30, 2014 | 86.68M |
| March 31, 2014 | 96.02M |
| December 31, 2013 | 96.64M |
| September 30, 2013 | 94.28M |
| June 30, 2013 | 88.10M |
| March 31, 2013 | 76.19M |
| December 31, 2012 | 70.04M |
| September 30, 2012 | 66.39M |
| June 30, 2012 | 60.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
32.20M
Minimum
Jun 2021
140.80M
Maximum
Dec 2019
67.02M
Average
72.35M
Median
Research and Development Expense (TTM) Benchmarks
| Abbott Laboratories | 2.795B |
| Novavax Inc | 451.49M |
| Insulet Corp | 201.00M |
| BioLife Solutions Inc | 15.99M |
| TransMedics Group Inc | 50.26M |